Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat

European Journal of Anaesthesiology

Volumn 20, Issue 3, 2003, Pages 205-211

  Carceles, M D ^a   Aleixandre, F ^a   Fuente, T ^a   Lopez Vidal J ^a   Laorden, M L ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Enzyme inhibitors, phosphodiesterase inhibitors, pimobendan, rolipram, zaprinast ischaemia, myocardial ischaemia; Nucleotides, cyclic, camp, cgmp; Rat

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PIMOBENDAN; ROLIPRAM; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOSE RESPONSE; DRUG EFFECT; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; INCIDENCE; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; PHARMACODYNAMICS; RADIOIMMUNOASSAY; RAT;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANESTHESIA; ANIMALS; ARRHYTHMIA; BLOOD PRESSURE; CORONARY VESSELS; CYCLIC AMP; CYCLIC GMP; HEART RATE; HEART VENTRICLES; LIGATION; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PURINONES; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM;

EID: 0037336457     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0265021503000358     Document Type: Article

References (27)

1. Podzuweit T. Early arrhythmias resulting from acute myocardial ischaemia; possible role of cyclic AMP. In: Parratt JR, ed. Early Arrhythnfias Resulting from Myocardial Ischaemia: Mechanisms and Prevention by Drugs. London, UK: Macmillan, 1982: 171-198.
2. Lubbe WF, Nguyen T, West EJ. Modulation of myocardial cyclic AMP and vulnerability to fibrillation in the rat heart. Fed Proc 1983; 42: 2460-2464.
3. Yoshida Y, Hirai M, Yamada T, et al. Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias: evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias. Circulation 2000; 101: 624-630.
4. Lubbe WF, Podzuweit T, Daries PS, Opie LH. The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart. J Clin Invest 1978; 61: 1260-1269.
5. Podzuweit T, Els DJ, McCarthy J. Cyclic AMP mediated arrhythmias induced in the ischaemic pig heart. Basic Res Cardiol 1981; 76: 443-448.
6. Kane KA, Morcillo-Sanchez EJ, Parratt JR, Rodger IW, Shahid M. The relationship between coronary artery occlusion-induced arrhythmias and myocardial cyclic nucleotide levels in the anaesthetized rat. Br J Pharmacol 1985; 84: 139-145.
7. Packer M. Effect ofphophodiesterase inhibitors on survival of patients with chronic congestive heart failure. Am J Ain j Cardiol 1989; 63: 41A-45A.
8. Pabla R, Bland-Ward P, Moore PK, Curtis MJ. An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart. Br J Pharmacol 1995; 116: 2923-2930.
9. Ellison WG, Ellison KE, Sweeney MO, Epstein LM, Maisel WH. Management of arrhythmias in heart failure. Cardiol Rev 2002; 10: 8-14.
10. Pamboukian SV, Carere RG, Webb JG, et al. The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Transplant 1999; 18: 367-371.
11. Skrabal MZ, Stading JA, Behmer-Miller KA, Hilleman DE. Advances in the treatment of congestive heart failure: new approaches for an old disease. Pharmacotherapy 2000; 20: 787-792.
12. Movsesian MA. Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. Expert Opin Investig Drugs 2000; 9: 963-973.
13. Carceles MD, Aleixandre F, Fuente T, López-Vidal J, Laorden ML. Combined phosphodiesterase inhibition and B-blockade in the GI104313, decreases ischemia-induced arrhythmias in the rat. Can J Anaesth 2001; 48: 486-492.
14. Clark C, Foreman MI, Kane KA, McDonald FM, Parrat JR. Coronary artery ligation in anaesthetized rats as a method for the production of experimental dysrrhythmias and for the determination of infarct size. J Pharmacol Meth 1980; 3: 357-358.
15. Hartree EF. Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 1972; 48: 442-446.
16. Marshall RJ, Muir AW, Winslow E. Development of a severe model of early coronary artery ligation-induced dysrrhythmias in the anaesthetized rat. Br J Pharmacol 1981; 73: 951-995.
17. Daugherty A, Frayn KN, Redfern WS, Woodward B. The role of catecholamines in the production of ischaemiainduced ventricular arrhythmias in the rat in vivo and in vitro. Br J Pharmacol 1986; 87: 265-277.
18. Holdbrook M, Coker SJ. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits. Br J Pharmacol 1991; 103: 1973-1979.
19. Jones RB, Frodsham G, Kickinson K, Foster GA. Effect of flosequinam on ischaemia-induced arrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. Br J Pharmacol 1993; 108: 1111-1116.
20. Sugiura M, Ogawa K, Yamazaki N. Concentration of myocardial cyclic AMP and ventricular fibrillation induced by aminophyline. Jpn Heart J 1979; 20: 177-182.
21. Colluci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. N Engl J Med 1986; 314: 349-358.
22. Lynch JJ, Kitzen JM, Hoff PT, Lucchesi BR. Effects of pimobendan (UD-CG 115 BS) a new positive inotropic molecule on ventricular tachycardia and ischemic ventricular fibrillation in a conscious canine model of recent myocardial infarction. Cardiovasc Pharmacol 1989; 12: 547-554.
23. Corr PB, Witkowski FX, Sobel BE. Mechanisms contributing to malignant dysrrhythmias induced by ischaemia in the cat. J Clin Invest 1978; 61: 109-119.
24. Worthington MG, Opie LH. Contrasting effects of cyclic AMP increase caused by β-adrenergic stimulation or by adenylate cyclase activation on ventricular fibrillation threshold of isolated rat heart. J Cardiovasc Pharmacol 1992; 20: 595-600.
25. Uno T, Kanayama H, Miyazaki Y, Ogawa K, Stake T. Increased cyclic GMP in atrial fibrillation. J Electrocardiol 1986; 19: 51-57.
26. +-exchange inhibition in regionally ischemic reperfused porcine hearts. J Cardiovasc Pharmacol 1997; 30: 235-240.
27. Hoag JB, Quian Y-Z, Nayeem MA, D'Angelo M, Kukreja RC. ATP-sensitive potassium channel mediates delayed ischemia protection by heat stress in rabbit heart. Am J Physiol 1997; 273: H2458-H2464.